Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2025-11-18 Major Shareholding Noti…
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 10(5) in respect of Regulation 10(1)(a)(i) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the proposed acquisition of shares by promoters and related parties, including shareholding percentages before and after the transaction, and compliance with takeover regulations. The content is focused on notifying stock exchanges and the public about a substantial acquisition of shares and related exemptions from open offer requirements. This type of filing corresponds to a Major Shareholding Notification (MRQ), which involves changes in significant share ownership levels and crossing thresholds as per regulatory requirements. The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about share acquisition and ownership changes.
2025-11-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on November 6, 2025, discussing the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. It includes detailed management commentary, financial highlights, and a Q&A session with analysts. The presence of a full transcript of the call, including management remarks and Q&A, clearly identifies this as a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA).
2025-11-10 English
Copy of Newspaper Publication
Regulatory Filings
2025-11-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of an audio recording of an earnings conference call for the quarter and half year ended 30th September 2025. It references the earnings conference call but does not contain the transcript itself or detailed financial data. The document is short (1597 characters) and serves as an announcement that the recording is available on the company's website. According to the 'Menu vs Meal' rule, this is an announcement about the availability of a call transcript, not the transcript itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about the earnings call recording availability, not the full transcript or financial report.
2025-11-06 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English
Giving guarantees/indemnity/ becoming a surety for third party
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (National Stock Exchange of India Limited and Bombay Stock Exchange Limited) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the approval of a corporate guarantee by the company's Committee of Executive Directors for a subsidiary's loan facility. The document includes details required under the regulation, such as the party for which the guarantee is given, promoter interest, terms of the guarantee, and its impact on the company. The document is short (3272 characters) and is an announcement of a corporate guarantee event, which relates to financing activities. It is not a full financial report, audit, or earnings release. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-10-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.